EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sodium-glucose cotransporter-2 inhibitors and risk of incident kidney disease in patients with gout

Fu-Shun Yen, Jing-Yang Huang, Yao-Min Hung, Chii-Min Hwu, Chih-Cheng Hsu, James Cheng-Chung Wei

Frontiers in Pharmacology · 17.11.2026 · 17

DOI: 10.3389/fphar.2026.1998539 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 17.11.2026. Verfasst von Fu-Shun Yen und 5 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This study aimed to compare the risk of kidney outcomes in patients with gout and type 2 diabetes (T2D) who used sodium-glucose cotransporter-2 inhibitors (SGLT2i) and those who did not.

Methods

Using the TriNetX US Collaborative Network, we conducted a retrospective cohort study comparing patients with gout and type 2 diabetes who initiated SGLT2i or dipeptidyl peptidase-4 inhibitors (DPP-4i). After 1:1 propensity score matching, 2,676 pairs were included in the primary active-comparator analysis. Kidney outcomes, hospitalization, and all-cause mortality were evaluated using Cox proportional hazards models. A comparison between SGLT2i users and nonusers was retained as a secondary analysis.

Results

In the primary analysis, SGLT2i initiation was associated with lower risks of composite kidney outcomes (HR, 0.848; 95% CI, 0.775–0.929), incident CKD (HR, 0.851; 95% CI, 0.777–0.932), and all-cause mortality (HR, 0.702; 95% CI, 0.571–0.864) compared with DPP-4i initiation. No statistically significant differences were observed in dialysis or kidney transplantation (HR, 0.685; 95% CI, 0.388–1.210) or all-cause hospitalization (HR, 0.941; 95% CI, 0.857–1.032). Findings from the secondary SGLT2i versus non-SGLT2i analysis were generally consistent.

Conclusion

Our study found that SGLT2i use in patients with gout and T2D was associated with a lower risk of developing CKD, and all-cause mortality, compared to those not using SGLT2i.

Zitieren

APA

Yen, F., Huang, J., Hung, Y., Hwu, C., Hsu, C., & Wei, J. C. (2026). Sodium-glucose cotransporter-2 inhibitors and risk of incident kidney disease in patients with gout. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1998539

Vancouver

Yen F, Huang J, Hung Y, Hwu C, Hsu C, Wei JC. Sodium-glucose cotransporter-2 inhibitors and risk of incident kidney disease in patients with gout. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1998539

BibTeX
@article{Yen2026,
  author = {Yen, Fu-Shun and Huang, Jing-Yang and Hung, Yao-Min and Hwu, Chii-Min and Hsu, Chih-Cheng and Wei, James Cheng-Chung},
  title = {Sodium-glucose cotransporter-2 inhibitors and risk of incident kidney disease in patients with gout},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1998539}
}
Kostenlos starten →